BMC Cancer (Aug 2024)

Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey

  • Tingting Zhang,
  • Chao Meng,
  • Wei He,
  • Tao Xu,
  • Yi Yang,
  • Chongqi Tu,
  • Ling Zhang,
  • Xiaofeng Sun,
  • Chunrong Zhu,
  • Xueyi Dang,
  • Ke Wang,
  • Chuan Chen,
  • Xiong Yan,
  • Huiting Xu,
  • Le Huang,
  • Enlai Jiang,
  • Feng Xia,
  • Xinming Zhou,
  • Shunkai Zhou,
  • Weidong Zang,
  • Xifeng Li,
  • Jin Zhang,
  • Jiaping Zheng,
  • Jianjun Xin,
  • Bin Huang,
  • Guopei Zhu,
  • Jiexiang Zhu,
  • Jun Liang

DOI
https://doi.org/10.1186/s12885-024-12832-3
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Data on long-term cancer survivors treated with apatinib are lacking. This study aimed to describe the characteristics of long-term cancer survivors after apatinib-based therapy, and to know about their satisfaction degree with apatinib and severity of depression and insomnia. Methods Patients with solid tumors who had received apatinib-based therapy for at least 5 years were invited to complete an online questionnaire. Characteristics of patients and treatment, knowledge of apatinib, satisfaction degree, and severity of depression and insomnia assessed by Patient Health Questionnaire-9 and Insomnia Severity Index were collected. Results Between December 8, 2023 and March 1, 2024, a total of 436 patients completed the online questionnaire. Most patients were satisfied with the efficacy (96.6%) and safety (93.1%) of apatinib, were willing to continue apatinib treatment (99.5%), and would recommend apatinib to other patients (93.3%). Continuous apatinib treatment resulted in significant negative impact on daily life, work, or study in only two (0.5%) patients. Almost all patients currently had no or mild depression (97.0%) and insomnia (97.9%) problems. The most common patient-reported adverse events were hand-foot syndrome (21.3%) and hypertension (18.3%). Conclusions Our survey showed a high satisfaction degree with apatinib in long-term cancer survivors. Long-term apatinib treatment resulted in almost no negative impact on patient’s quality of life.

Keywords